IXICO Strengthens Position in Parkinson’s Disease Clinical Trials

April 4, 2016
News

Joins ground breaking consortium and awarded five year contract

Read full press release here

4 April 2016, IXICO plc (Ticker: IXI) (‘IXICO’ or the ‘Company’), the brain health company, today announces two further milestones in its growing Parkinson’s disease franchise. 

IXICO has joined seven global pharmaceutical companies including: AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp & Dohme, Pfizer, and UCB in the ground breaking Critical Path for Parkinson’s Consortium (CPP).  Formed by Parkinson’s UK and the Critical Path Institute, CPP has a common goal of establishing best practices and more efficient protocols for clinical trial planning.  Data from previous Parkinson’s trials will be collected, standardized and integrated to inform new approaches to designing clinical trials focused on early-stage Parkinson’s disease.  CPP brings together researchers, drug companies and regulators with the aim to accelerate the development of safe and effective therapies for Parkinson’s disease. 

Furthermore, IXICO has been awarded a contract by Oxford BioMedica to support the use of novel brain scanning in a clinical trial of a novel experimental drug for Parkinson’s disease, OXB-102.  This study is expected to start in mid-2016 and is a phase I/II study to evaluate the safety and tolerability of OXB-102 and establish the optimal dose in the study patient population.  IXICO will be involved for up to 5 years including long-term follow up and will apply its PET imaging expertise, image data handling and analysis technology to oversee the manufacture and use of novel radiopharmaceutical ligands, at specialist imaging centres in Europe. 

Professor Derek Hill, IXICO Chief Executive Officer, commented:

“This is a time of great innovation in the design of clinical trials of new treatments for Parkinson’s disease.  It is a privilege to be joining these major global pharmaceutical companies and Parkinson’s UK in the Critical Path Institute’s CPP consortium and to work together to accelerate progress in developing new therapies for Parkinson’s disease patients.  In addition, we are delighted to be awarded the Parkinson’s contract with Oxford BioMedica which highlights our growing reputation as a leading provider of digital technology in brain health.” 

 

Enquiries:

IXICO plc

+44 20 3763 7499

Derek Hill, CEO

 

Susan Lowther, CFO

 

Peel Hunt LLP (Nominated Adviser and Broker)

+44 20 7418 8900

James Steel / Oliver Jackson

 

Daniel Stewart & Company (Joint Broker)

+44 207 776 6550

Martin Lampshire / David Coffman

 

FTI Consulting Limited (Investor Relations)

+44 20 3727 1000

Simon Conway / Mo Noonan / Matthew Moss

 

Notes to Editors

About IXICO

IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, multiple sclerosis, Parkinson’s disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

­­­­­­­­­­­­­­­­­­­­­­­­­

About the Critical Path Institute

Critical Path Institute, founded in 2005 in Tucson, Arizona, is an independent, non-profit organization dedicated to bringing scientists from the FDA, industry and academia all together to collaborate and improve the drug development and regulatory process for medical products. [Move to main text, can you include the global pharma members?]

More information is available on www.c-path.org